Warnings
Chronic administration of corticotropin may lead to adverse effects which are not reversible. Corticotropin may only suppress symptoms and signs of chronic diseases without altering the natural course of the disease. H.P. Acthar Gel (Repository Corticotropin Injection) should not be administered for treatment until adrenal responsiveness has been verified with the route of administration which will be utilized during treatment, intramuscularly or subcutaneously. A rise in urinary and plasma corticosteroid values provides direct evidence of a stimulatory effect. Prolonged administration of corticotropin increases the risk of hypersensitivity reactions. Although the action of corticotropin is similar to that of exogenous adrenocortical steroids, the quantity of adrenocorticoid may be variable. In patients who receive prolonged corticotropin therapy, the additional use of rapidly acting corticosteroids before, during, and after an unusual stressful situation is indicated.
Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
Corticotropin may mask some signs of infection, and new infections including those of the eye due to fungi or viruses may appear during its use. There may be decreased resistance and inability to localize infection when corticotropin is used.
Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. Dietary salt restriction and potassium supplementation may be necessary. Corticotropin increases calcium excretion.
While on corticotropin therapy, patients should not be vaccinated against smallpox. Other immunization procedures should be undertaken with caution in patients who are receiving corticotropin, especially when high doses are administered because of the possible hazards of neurological complications and lack of antibody response.